Reviva Pharmaceuticals Holdings (RVPH) Cash from Operations (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted Cash from Operations of 3801296.0 for Q1 2026, up 34.44% sequentially from 5798211.0 in Q4 2025, and up 53.61% YoY from 2474642.46 in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) Cash from Operations (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported Cash from Operations for 9 years, with the latest figure at 3801296.0 in Q1 2026.
- Quarterly Cash from Operations rose 53.61% year-over-year to 3801296.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20201741.0 (up 32.69% YoY) and the FY2025 annual result came in at 24594643.0, up 26.68% from the prior year.
- Cash from Operations advanced to 3801296.0 in Q1 2026 per RVPH's latest filing, from 5798211.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 3801296.0 in Q1 2026 and troughed at 11725809.0 in Q1 2024.
- A 5-year average of 6424987.59 and a median of 5798211.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2026: Cash from Operations slumped 198.43% in 2022, then soared 53.61% in 2026.
- Over 5 years, Cash from Operations stood at 4690634.0 in 2022, then tumbled by 89.24% to 8876445.0 in 2023, then dropped by 2.52% to 9100497.0 in 2024, then soared by 36.29% to 5798211.0 in 2025, then surged by 34.44% to 3801296.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 3801296.0, 5798211.0, and 5589486.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.74 Mn | 6.74 Mn | - | -2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.12 Mn |
| Jun 30, 2026 | -2.12 Mn |
| Mar 31, 2026 | -3.80 Mn |
| Mar 31, 2026 | -3.80 Mn |
| Dec 31, 2025 | -5.80 Mn |
| Dec 31, 2025 | -5.80 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Sep 30, 2025 | -5.59 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Jun 30, 2025 | -5.01 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -9.10 Mn |
| Dec 31, 2024 | -9.10 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Sep 30, 2024 | -4.24 Mn |
| Jun 30, 2024 | -8.48 Mn |
| Jun 30, 2024 | -8.48 Mn |
| Mar 31, 2024 | -11.73 Mn |
| Mar 31, 2024 | -11.73 Mn |